<DOC>
	<DOCNO>NCT01513122</DOCNO>
	<brief_summary>The use anti HIV drug ( ART ) , particular class drug know nucleoside reverse transcriptase inhibitor ( N ( ) RTI ) , associate change body fat particular loss peripheral fat limb . Low bone mineral density osteoporosis also common HIV-infected patient . There appear association ART bone loss , poorly understood require research . The SECOND-LINE study provide opportunity examine new anti-HIV drug ( raltegravir ) result great increase limb fat drug regimen contain N ( ) RTI , currently standard care . This study also provide opportunity examine additional bone loss occur second regimen anti-HIV drug whether non-N ( ) RTI regimens ART use second line therapy result less bone loss use class anti-HIV drug protease inhibitor N ( ) RTI combination . It hypothesize subject randomise Raltegravir arm demonstrate great increase limb fat small reduction bone density proximal femur 48 week randomise control arm ( LPV/r + 2-3N ( ) RTIs ) .</brief_summary>
	<brief_title>Bone Body Comp : A Sub Study SECOND-LINE Study</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>SecondLine main study identifier : NCT00931463 1 . HIV1 positive license diagnostic test 2 . Aged 16 year old ( minimum age determine local regulation legal requirement dictate ) 3 . Have receive first antiretroviral regimen consist NNRTI plus 2N ( ) RTIs ≥ 24 week 4 . No change antiretroviral therapy within 12 week prior screen 5 . Failed firstline NNRTI + 2N ( ) RTI combination therapy accord virological criterion define two consecutive ( ≥7 day apart ) HIV RNA result &gt; 500 copies/mL 6 . No prior current exposure HIV protease inhibitor and/or HIV integrase inhibitor 7 . Able provide write informed consent 1 . The following laboratory variable : absolute neutrophil count ( ANC ) &lt; 500 cells/µL hemoglobin &lt; 7.0 g/dL platelet count &lt; 50,000 cells/µL ALT &gt; 5 x ULN 2 . Pregnant nursing mother 3 . Participants active viral hepatitis B infection define presence serum hepatitis B surface antigen 4 . Use immunomodulators within 30 day prior screen 5 . Use prohibit medication ( rifampicin , midazolam , triazolam , cisapride , pimozide , amiodarone , dihydroergotamine , ergotamine , ergonovine , methylergonovine , astemizole , terfenadine , vardenafil , St. John 's wort ) 6 . Intercurrent illness require hospitalisation 7 . Active opportunistic disease adequate control opinion site Principal Investigator 8 . Participants current alcohol illicit substance abuse opinion site Principal Investigator might adversely affect participation study 9 . Participants deem site Principal Investigator unlikely able remain followup protocoldefined period</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>